Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth

Antony, France (ots/PRNewswire) -

- 1st Half-Year Sales Up 16%

- Revision Upwards of 2008 Sales Growth Guidance:
(greater than or equal to)12%

ANTONY, France, July 10 /PRNewswire/ --

EUR millions 2006 2007 07/06 2008 08/07
EURM %Sales EURM %Sales % EURM %Sales %
change change
Southern Europe (1) 20.5 72 23.2 72 13 26.8 71 15
Other EU countries (2) 6.9 24 7.7 24 11 9.3 24 20
Other markets 1.2 4 1.3 4 15 2.0 5 47
SLIT 21.8 76 25.1 77 15 30.4 80 21
SCIT 5.4 19 5.6 18 5 6.1 16 7
Other products 1.5 5 1.5 5 (0) 1.6 4 4
Total Q2 sales 28.6 100 32.2 100 13 38.0 100 18
Southern Europe (1) 48.1 75 56.5 76 18 64.7 75 14
Other EU countries (2) 13.7 21 15.8 21 15 18.6 21 18
Other markets 2.4 4 2.5 3 5 3.7 4 46
SLIT 49.4 77 59.7 80 21 71.3 82 19
SCIT 11.6 18 11.8 16 2 12.3 14 4
Other products 3.2 5 3.2 4 3 3.4 4 6
Total H1 sales 64.2 100 74.8 100 17 87.0 100 16
(1) Portugal, Spain, France, Italy, Greece; (2) Switzerland included

2008 second quarter sales recorded strong growth in all markets
(+18% vs +13% in 2007). Eastern European markets and other markets
outside Europe made a significant contribution to this growth. The
most buoyant segment of the market remained desensitisation via the
sublingual route (SLIT, +21%, vs +15% in 2007) whose reputation was
enhanced by the launch of allergen tablets.

Cumulated sales for the first half-year increased by 16% compared
to the first half 2007, when growth was already particularly strong
(+ 17%). This good performance has enabled the Group to revise its
sales growth guidance upwards to growth of at least 12% in 2008 (vs
(greater than or equal to)10% previously), boosted by the growing
success of the sublingual route, in which Stallergenes continues to
strengthen its leadership.

The commercial launch of ORALAIR(R) Grasses for adults will take
place in Germany in the next few weeks, following the grant, on 24
June 2008, of the marketing authorisation. The request for a
paediatric extension of ORALAIR(R) Grasses has been filed with the
Paul Ehrlich Institute. The application for clinical studies for
ORALAIR(R) Grasses in the US will be filed in July.

The 2008 first half-year financial results will benefit from a
strong level of activity and will show a marked improvement compared
to 2007. These results will be released on 27 August 2008.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to
desensitisation therapies for the prevention and treatment of
allergy-related respiratory diseases, e.g. rhino-conjunctivitis and
allergic asthma. A pioneer and leader in sublingual desensitisation
treatment, Stallergenes devotes 16% of its turnover to Research and
Development and is actively involved in the development of a new
therapeutic class: sublingual desensitisation tablets.

In 2007, Stallergenes had a turnover of 147 million euros and
provided desensitisation treatments to more than 500,000 patients.

Stallergenes is listed in Euronext Paris (Compartment B) and
is part of the sample composing the SBF 120 index.
ISIN Code: FR0000065674
Reuters Code: GEN.PA
Bloomberg Code: GEN.FP

Additional information is available on
http://www.stallergenes.com

ots Originaltext: Stallergenes
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Contacts: Albert Saporta - Chairman, Tel.: +33-1-55-59-20-04;
Christian Thiry- Chief Financial Officer, Tell.: +33-1-55-59-20-95 -
e-mail : investorrelations@stallergenes.fr . Press Relations
Stallergenes: Lise Lemonnier - Communications Manager, Tel.:
+33-1-55-59-20-96 - e-mail : llemonnier@stallergenes.fr ; Investors
and analysts relations: Pavie Finance, Lucile de Fraguier - Tel.:
+33-1-42-15-04-39, E-mail: contact@pavie-finance.com .